tradingkey.logo
tradingkey.logo
Search

AIM ImmunoTech Inc

AIM
Add to Watchlist
0.279USD
-0.017-5.84%
Close 06/30, 16:00ETQuotes delayed by 15 min
2.29MMarket Cap
LossP/E TTM

TradingKey Stock Score of AIM ImmunoTech Inc

Currency: USD Updated: 2026-06-30

Key Insights

AIM ImmunoTech Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 175 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.25.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AIM ImmunoTech Inc's Score

Industry at a Glance

Industry Ranking
175 / 387
Overall Ranking
305 / 4569
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

AIM ImmunoTech Inc Highlights

StrengthsRisks
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Growing
The company is in a growing phase, with the latest annual income totaling USD 88.00K.
Fairly Valued
The company’s latest PE is -0.07, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 105.74K shares, decreasing 41.27% quarter-over-quarter.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
5.250
Target Price
+1672.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of AIM ImmunoTech Inc?

The TradingKey Stock Score provides a comprehensive assessment of AIM ImmunoTech Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of AIM ImmunoTech Inc’s performance and outlook.

How do we generate the financial health score of AIM ImmunoTech Inc?

To generate the financial health score of AIM ImmunoTech Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects AIM ImmunoTech Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of AIM ImmunoTech Inc.

How do we generate the company valuation score of AIM ImmunoTech Inc?

To generate the company valuation score of AIM ImmunoTech Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare AIM ImmunoTech Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of AIM ImmunoTech Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of AIM ImmunoTech Inc.

How do we generate the earnings forecast score of AIM ImmunoTech Inc?

To calculate the earnings forecast score of AIM ImmunoTech Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on AIM ImmunoTech Inc’s future.

How do we generate the price momentum score of AIM ImmunoTech Inc?

When generating the price momentum score for AIM ImmunoTech Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of AIM ImmunoTech Inc’s prices. A higher score indicates a more stable short-term price trend for AIM ImmunoTech Inc.

How do we generate the institutional confidence score of AIM ImmunoTech Inc?

To generate the institutional confidence score of AIM ImmunoTech Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about AIM ImmunoTech Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of AIM ImmunoTech Inc.

How do we generate the risk management score of AIM ImmunoTech Inc?

To assess the risk management score of AIM ImmunoTech Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of AIM ImmunoTech Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of AIM ImmunoTech Inc.
KeyAI